Trial Profile
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin 320 (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 09 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 22 Sep 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2015, as reported by ClinicalTrials.gov record.